Perspective Therapeutics (CATX) Gross Profit (2010 - 2023)

Perspective Therapeutics (CATX) has 14 years of Gross Profit data on file, last reported at -$1.0 million in Q4 2023.

• For the quarter ending Q4 2023, Gross Profit changed N/A year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2023 stood at $463000.0 (down 92.97% YoY), and the FY2024 full-year result was $614000.0, up 32.61% from the prior year.
• Gross Profit declined to -$1.0 million in Q4 2023, from $738000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $2.8 million in Q3 2022 to a low of -$1.0 million in Q4 2023.
• A 5-year average of $1.1 million and a median of $1.2 million in 2020 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit jumped 170.26% in 2022 and plunged 89.52% in 2023, its largest moves.
• Tracing CATX's Gross Profit over 5 years: stood at $1.1 million in 2019, then advanced by 5.04% to $1.2 million in 2020, then rose by 4.54% to $1.2 million in 2021, then soared by 127.95% to $2.8 million in 2022, then sank by 136.32% to -$1.0 million in 2023.
• Business Quant data shows CATX's Gross Profit at -$1.0 million in Q4 2023, $738000.0 in Q3 2023, and $248000.0 in Q2 2023.